Backed by Cencora, Optum, and Binny Bansal, RISA aims to bring its oncology AI OS deeper into cancer clinics, health systems, and infusion networks.
RISA Labs, a Palo Alto-based healthcare AI startup, has raised $11.1 million (â‚ą100 Cr+) in its Series A round co-led by Cencora Ventures and Optum Ventures. The funding also saw participation from Oncology Ventures, z21 Ventures, and General Catalyst cofounder John Simon via VentureForGood.
The capital will fuel wider distribution of RISA’s AI-powered oncology workflow system across the US healthcare ecosystem, including cancer clinics, specialty pharmacies, and infusion networks.
“RISA is built for the realities of modern oncology—not just to simplify, but to solve,” said cofounder Kshitij Jaggi.
Cracking Cancer Workflows with AI Agents
Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, RISA Labs is the maker of BOSS (Bio-Oncology System Software)—an AI operating system designed to automate and optimize complex oncology workflows.
Key capabilities include:
- Breaking workflows into discrete, manageable tasks handled by specialized AI agents
- Navigating multi-drug regimens, payer rules, and disease-specific protocols
- Reducing manual overhead in a data-heavy, compliance-intensive environment
In active deployments, RISA claims:
- 80% reduction in administrative workload
- Up to 40% decrease in insurance denials
- 97.8% first-pass approval rate for treatments
Can AI truly handle the clinical chaos of cancer care? RISA is betting on it.
Strategic Backing and Growth Momentum
This latest round adds to RISA’s $3.5M seed capital raised earlier from Odd Bird VC, Ashish Gupta (Helion), and Flipkart cofounder Binny Bansal, among others. It was also featured in Inc42’s “30 Startups to Watch” (April 2025)—a nod to its fast rise.
Now, with support from top-tier healthcare investors, the startup plans to:
- Deepen its footprint across oncology networks in 2026
- Partner with ecosystem leaders to integrate AI-driven workflows across the full cancer care continuum
- Invest in local deployment teams, integrations, and clinical support for US clients
The move aligns with a broader investor surge into AI-powered healthtech, driven by the need to accelerate diagnosis, reduce friction in care delivery, and optimize reimbursement systems.
AI’s Expanding Role in Healthtech
Healthcare is undergoing an AI renaissance—where data-driven decision-making is no longer optional but essential. According to Inc42’s Startup Trends Report, healthtech ranked among India’s top 10 funded sectors in 2025, with $700M+ deployed across 54 deals.
Other recent signals include:
- CrisprBits raising $3M to scale its molecular diagnostics platform
- A growing cohort of AI-first diagnostic and workflow startups attracting global capital
RISA’s bet? That oncology’s complexity demands not just AI assistance—but an AI operating system at the heart of care delivery.
TL;DR
RISA Labs raised $11.1M in Series A led by Cencora and Optum Ventures to expand its AI oncology workflow system across the US. Backed by Binny Bansal and other key investors, RISA automates complex cancer care processes and has shown 80% admin time savings and 97.8% approval rates in active units.
AI summary
- RISA Labs raised $11.1M from Cencora, Optum, Oncology Ventures, others
- Funding to scale AI OS for cancer care across clinics, pharmacies, infusion networks
- Platform automates oncology workflows, improves approval rates
- Previously raised $3.5M from Binny Bansal, Ashish Gupta
- Healthtech funding crosses $700M in 2025, signaling deep investor interest
